Outsourced Medical Sales – How to Find Pharma Trends, Opportunities and Potential Revenues Are you interested in the future of outsourced pharmaceutical sales? If so, gain new multilevel forecasts for those promotional activities. With our updated report, stay ahead in data on contract sales organisations (CSOs).
See what revenues are possible. Also assess changes sweeping that industry. Avoid getting left behind.
Knowledge to help your work – discover how you can benefit your influence So avoid struggles to find data on outsourced drug selling. Our report helps your research, analyses and decisions for medical sales. Save time, too, and help yourself stay ahead in knowledge. Also benefit your authority and reputation for insight.
Please read on now to investigate that expanding healthcare industry, seeing what future sales it could generate. Assess the potential gains.
Forecasts and other information showing you pharma sales contracting’s potential Expanding drug sales worldwide increase the use of out-contracted services for promoting and selling human medicines. There, from 2016, see what is possible.
Besides forecasting revenues to 2026, our new analysis shows you recent results, sales growth rates and market shares. That way you assess companies’ outlooks and potentials. Our report gives you 84 tables, 64 charts and three interviews with that industry.
The following sections show how that investigation helps your work.
Predictions for that world market and its segments – what sales are possible? What are the secrets of that industry’s progress? And what is its potential? Discover in our report overall world revenue to 2026 for contract pharma sales operations.
Also see individual predictions of revenues to 2026 for 11 submarkets at world level: • Contract detailing (personal promotion/field sales) • Contract non-personal promotion, with further sub-forecasting for teledetailing, eDetailing and other selling operations • Medical education services • Sample management services.
You also gain revenue forecasting to 2026 for therapeutic segments: • Cardiovascular disease • Metabolic disorders • Cancer treatment • Other drugs (grouped prediction).
There you assess prospects for outsourced medicine selling, hearing where you can gain. Investigate competition and rising sales. Discover revenue potentials for syndicated pharma sales teams and related promotional activities.
Our investigation also shows you geographical predictions for CSOs.
Healthcare in national markets – commercial outlooks for medical sales contracting Our study shows countries having great potential for those outsourced and off-shored selling operations. See where and how you could profit, assessing predicted revenues.
Our analyses show you individual revenue forecasts to 2026 for 11 national markets: • USA • Japan • Germany, UK, France, Italy and Spain (EU5 countries) • China, India, Brazil and Russia (BRIC group).
In our study you find regions and countries with highest revenues, demand and potential sales growth. Stay ahead, then, for information. Find international prospects for that promoting and selling to doctors and other medical practitioners.
And what events change that market? Our work explains, discussing trends, technologies and service needs.
Developments, challenges and events influencing contract sales organisations Our investigation explains issues affecting the CSO industry and market from 2016: • Outsourced and in-house sales reps – trends and emerging sales models, including multiple channels (multichannel marketing to medical professionals) • Services CSOs offer and benefits to drug companies outsourcing medical sales • Maturing brands and product launches, including flexibility in field sales teams • Legislation and new market access requirements for pharma sales representatives – assess changing regulations and see their effects • Changes to online marketing and potential for IT technologies – explore the changing environment for pharma sales • Risk-sharing agreements, key account management (KAM), key opinion leaders (KOLs) and medical science liaison (MSL).
And you explore these influences, too, among others shaping that market: • Smartphones and tablets for detailing – advances in communication technology for medical sales reps • Closed loop marketing (CLM), cloud computing and customer relationship management (CRM), including social media and big data • Changes to in-house sales staffing levels – rising demand for outsourcing service providers • Demand for inside and outside medical sales teams, as well as increasing needs for contact centres • Strategic partnering, mergers and acquisitions – links, networks and alliances • Promotion of biologics, biosimilars, orphan drugs and other specialty medicines.
With our analysis you investigate what stimulates and restrains competitors in that industry. Explore what affects its results. Also see how companies compete and what opportunities and potentials their future market holds.
Leading CSOs and potential for sales increases – what gains are possible? Our new study predicts the world market for pharma contract selling will rise to $7.36bn in 2020, with strong revenue expansion from 2016 to 2026. Those services have increasing demand. See what is possible.
So what happens next? Large pharma service contractors and specialists can prosper from 2016, expanding their business. Discover the potential sales gains.
In particular, our report assesses leading companies, including these: • Quintiles • UDG Healthcare • inVentiv Health • Publicis Touchpoint Solutions • OnCall.
There you analyse organisations’ results, capabilities and outlooks. You also see interviews with three firms – OnCall, Apodi and Hilver. Discover what pharma outsourcing providers say and do, helping you stay ahead in knowledge.
6 Ways Pharma Contract Sales Market 2016-2026 helps your work In these six main ways, our updated investigation benefits your research, analyses, plans and decisions: • World revenue for contract sales to 2026, with that market also divided into 11 service submarket forecasts – assess prospects for CSO business expansion • Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia – investigate developed and developing countries for expanding revenues • Outlooks for established and rising companies – explore service providers’ results, partnerships, technologies, portfolios and strategies • Competition and opportunities – investigate what shapes that medical promotion industry’s future, including ways to develop business in drug selling • Analysis of what stimulates and restrains medical sales – assess commercial challenges and strengths, helping you compete and gain advantages • Interviews with three companies – OnCall, Apodi and Hilver – discover what other authorities in that field say and do, helping you stay ahead.
Knowledge found nowhere else, helping your research, plans and presentations Our report gives independent analysis. With that data you are less likely to fall behind in knowledge or miss opportunity. See what is possible, getting independent business information by our UK-based in-house analysts.
Through your choice now, discover how you could save time and effort, also benefiting your influence and reputation for commercial insight.
Predictions for outsourced drug promotion – gain by trying our investigation Our new study is for everyone investigating pharmaceutical selling. There find revenue forecasting to 2026, with discussions and other information. Avoid missing out on data to help you stay ahead. Benefit your work by getting our report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Pharma Contract Sales Overview 1.2 Why You Should Read This Report 1.3 How this Report Delivers 1.4 Main Questions Answered by this Report 1.5 Who is this Report for? 1.6 Research and Analysis Methods 1.7 Frequently Asked Questions (FAQ) 1.8 Some Associated Reports 1.9 About Visiongain
2. Introduction to and Definition of the Pharma Contract Sales Market 2.1 Defining the Market 2.2 What is a CSO? 2.3 What Services do CSOs Provide? 2.4 The Different Marketing Channels Employed by Pharma Companies in 2016 2.5 Growing Trend of Outsourcing in the Overall Pharma Industry 2.6 The Rise in Pharma Contract Sales 2.7 Detailing: Becoming Less Relevant or is it as Important as Ever? 2.7.1 Declining Access to Doctors: Trend Continues in 2016 2.8 Large Cuts in Sales Force in Various Companies 2.9 Companies Cannot Rely Solely Upon Detailing 2.9.1 Trends Driving the Need for New Sales Models
3. Global Pharma Contract Sales Market 2016-2026 3.1 The Market in 2015 3.2 Global Pharma Contract Sales Market 2010-2015 3.2.1 Decent Growth in Past Six Years 3.3 Global Pharma Contract Sales Market 2016-2026 3.4 The Factors that will Drive Growth in this Market: Advantages of Outsourcing Pharma Sales 3.4.1 Cost and Flexibility 3.4.2 New Technologies and Sales Models 3.4.3 Emerging Markets and Mature Brands 3.4.4 Biosimilars 3.4.5 Account Management, Medical Education and Patient Support Services 3.4.6 Market Access Complexities Provide its Own Opportunities for CSOs 3.4.7 New Drug Launches 3.4.8 Summary 3.5 The Factors that will Restrain Growth in this Market: Disadvantages of Outsourcing Pharma Sales 3.6 Leading Therapeutic Submarkets for Pharma Contract Sales, Forecast 2016-2026 3.7 How Will the Therapeutic Composition of the Market Change Between now and 2026? 3.8 Contract Sales for Cardiovascular Drugs 3.8.1 Current Status 3.8.2 Recent Cardiovascular Drug Patent Expiries and FDA Approvals 3.8.3 Cardiovascular and Cerebrovascular Conditions are the World’s Most Fatal Diseases 3.8.4 Contract Sales for Cardiovascular Drugs: Submarket Forecast 2016-2026 3.9 Contract Sales for Metabolic Disorder Drugs 3.9.1 Current Status 3.9.2 430 Million People Expected to be Diagnosed with Diabetes by 2030 3.9.3 Contract Sales for Metabolic Disorders: Submarket Forecast 2016-2026 3.10 Contract Sales for Oncology Drugs 3.10.1 Current Status 3.10.2 Patent Expiries and Recent Approvals 3.10.3 Contract Sales for Oncology Drugs Forecast 2016-2026
4. Leading Service Sectors of the Pharma Contract Sales Market 2016-2026 4.1 The Leading Services 4.1.1 Leading Service Sectors of the Market, Forecast 2016-2026 4.1.2 How Will the Service Composition over the Market Change over the Next Ten Years? 4.2 Contract Detailing Submarket 4.2.1 Are we in the Midst of a Turnaround in Sales Rep Numbers in the Overall Pharma Industry? 4.2.2 What are the Trends in Sales Reps Employed by CSOs? 4.2.3 Detailing Services Offered by CSOs 4.2.4 CSOs will be Impacted by Declining Physician Access as Much as In-House Reps 4.2.5 Contract Detailing Submarket Forecast 2016-2026 4.2.6 Drivers and Restraints for this Dominant Service Submarket 4.3 Contract Non-Personal Promotion 4.3.1 The Benefits for both Pharma Companies and Doctors 4.3.2 Contract Non-Personal Promotion Submarket Forecast 2016-2026 4.3.3 Drivers and Restraints for Contract Non-Personal Promotion: Multichannel Marketing in the 21st Century 4.3.4 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Teledetailing and EDetailing 4.3.4.1 Contract Teledetailing Submarket: Current Status 4.3.4.2 Contract Teledetailing Submarket Forecast 2016-2026 4.3.4.3 Drivers and Restraints for Outsourced Teledetailing 4.3.4.4 Contract eDetailing Current Status 4.3.4.5 Contract eDetailing Submarket Forecast 2016-2026 4.3.4.6 Drivers and Restraints for Outsourced eDetailing 4.4 Medical Education Services Submarket Current Status 4.4.1 Medical Education Services Submarket Forecast 2016-2026 4.4.2 Medical Education Services Drivers and Restraints 4.5 Sample Management Services Submarket: Current Status 4.5.1 Sample Management Services Submarket Forecast 2016-2026 4.5.2 Drivers and Restraints for the Sample Management Services Submarket 4.5.3 J. Knipper and Company Inc: A US Leader in Sample Management Services 4.5.3.1 Company Acquires Sample Management Divisions from Leading CSOs 2010-2014 4.5.3.2 Construction Underway for New State of the Art Distribution Centre 4.5.3.3 New Multi-Million Dollar Contact Centre Opened 4.5.3.4 New Technologies to Drive Growth Over Next Ten Years
5. Leading National Markets for Pharma Contract Sales: Regulatory and Commercial Outlook 2016-2026 5.1 Current Leading National Markets 5.2 Leading Regional Markets Forecast 2016-2026 5.3 How will the Regional Composition of the Market Change between now and 2026? 5.4 Pharma Sales Regulatory Developments 5.4.1 Physician Payment Legislation in the US, Europe and Japan 5.4.1.1 The Physician Payment Sunshine Act (PPSA) 5.4.1.2 Proposed Bill to Close a Large Loophole in the PPSA, Could Come into Effect in 2017 5.4.1.3 Physician Payments in France: Increased Scrutiny 5.4.2 Domestic and International Concerns over Bribery: Recent Legislation in the US and UK 5.4.2.1 Promotional Products in the EU: New Rules 5.4.3 New Market Access Requirements in EU5 Countries 5.4.3.1 AMNOG: Stricter Pricing for Drugs in Germany 5.4.3.2 AMNOG: Has Reduced Prices of Top Sellers by 23% 5.4.3.3 Healthcare Reform in France: Pricing and Reimbursements have been set to Change for a While, is 2016 the Year it Finally Happens? 5.4.3.4 PCTs Replaced by CCGs in the UK 5.4.3.5 Pricing in the UK: Contentious Issue 5.4.4 Overtime for Sales Reps in the US: Rule Clarifications 5.5 US Pharma Contract Sales Market 5.5.1 Has Come a Long Way 5.5.2 Pharma Sales Regulation in the US 5.5.3 Trends in 2015 as Witnessed by a Large CSO 5.5.4 US Pharma Contract Sales Market Forecast 2016-2026 5.6 EU5 Pharma Contract Sales Market 5.6.1 Regulating Pharma Sales in the EU 5.6.2 Overall EU5 Pharma Contract Sales Market Forecast 2016-2026 5.6.3 UK Pharma Contract Sales Market Forecast 2016-2026 5.6.4 German Pharma Contract Sales Market Forecast 2016-2026 5.6.5 French Pharma Contract Sales Market Forecast 2016-2026 5.6.6 Italian Pharma Contract Sales Market Forecast 2016-2026 5.6.7 Spanish Pharma Contract Sales Market Forecast 2016-2026 5.7 Japanese Pharma Contract Sales Market 5.7.1 Regulation 5.7.2 Trends in 2015 as Witnessed by a Large CSO 5.7.3 Current Market Landscape 5.7.4 Japanese Pharma Contract Sales Market Forecast 2016-2026
6. Leading Emerging Markets for Pharma Contract Sales: Regulatory and Commercial Outlook 2016-2026 6.1 Pharma Contract Sales in Leading Emerging Markets in 2015 6.2 BRIC Pharma Contract Sales Markets Forecast 2016-2026 6.3 Chinese Pharma Contract Sales Market 6.3.1 Current Pharma Contract Sales Landscape in China 6.3.2 Rising In-House and Outsourced Sales Numbers 6.3.3 Concerns over Bribery 6.3.4 Chinese Pharma Contract Sales Market Forecast 2016-2026 6.4 Indian Pharma Contract Sales Market 6.4.1 Current Pharma Contract Landscape in India 6.4.2 Government and Regulatory Guidelines for Interactions Between Healthcare Professionals and Pharma Companies 6.4.3 Indian Pharma Contract Sales Market Forecast 2016-2026 6.5 Brazilian Pharma Contract Sales Market 6.5.1 Current Pharma Contract Sales Landscape in Brazil 6.5.2 State Payment Rules and Online Marketing Rules for Prescription Drugs 6.5.3 Brazilian Pharma Contract Sales Market Forecast 2016-2026 6.6 Russian Pharma Contract Sales Market 6.6.1 Current Pharma Contract Sales Landscape in Russia 6.6.2 New State Procurement Rules for Drugs Introduced in 2013 6.6.3 Tougher Rules on Interactions Between Doctors and Sales Reps in Russia 6.6.4 Russian Pharma Contract Sales Market Forecast 2016-2026
7. Pharma Contract Sales: Industry and Market Trends 2016-2026 7.1 Strengths and Weaknesses for the Global Pharma Contract Sales Market 2016-2026 7.2 Opportunities and Threats for the Global Pharma Contract Sales Market 2016-2026 7.3 Pharma Contract Sales Market: STEP Analysis 2016-2026 7.3.1 Social Factors Affecting Pharma Contract Sales to 2026 7.3.1.1 The Role of Ethics in Pharma Sales 7.4 Technological Developments to Improve Sales Strategies 7.4.1 Advantages of Using Tablets and Smartphones for Detailing 7.4.1.1 CSOs Need to Maximise on the Benefits of New Technologies 7.4.2 Closed Loop Marketing (CLM) 7.4.3 Customer Relationship Management (CRM) 7.4.4 The Advantages of Cloud Computing in Pharma Contract Sales 7.4.5 Does Big Data Have a Role in Pharma Sales? 7.4.6 Social Media in Relation to Pharma Sales 7.4.6.1 FDA Releases Long-Awaited Guidance on the use of Social Media 7.4.6.2 Pharma Industry is not Using Social Media to its Full Potential, but it Offers many Benefits 7.5 Economic Pressures are Limiting Healthcare and Marketing Budgets 7.6 Political Issues: Stricter Regulations for Pharma Sales around the World 7.7 Trends in Pharma Contract Sales 2016-2026 7.7.1 Cuts to In-House Sales Staff will Continue 2016-2026 7.7.2 There will be in an Increase in Strategic Partnering in Order to Provide Long-Term Revenue Growth 7.7.3 Leading CSOs have Consolidated, and will Continue to Consolidate, in Order to Increase Market Penetration 7.7.4 CSOs and Pharma Clients Alike Need to Stay Vigilant about the Risks of Outsourcing Pharma Sales 7.8 Drug Development Trends Affecting Pharma Sales 2016-2026 7.8.1 How will Orphan Drug Diseases Influence Pharma Contract Sales? 7.8.2 Promotion for Biosimilar Drugs over the Next Ten Years 7.8.3 There will be Greater Demand for Specialty Medicines 7.8.4 Emerging National Markets are Becoming Increasingly Important 7.9 Sales Models Need to Evolve with the Times 7.9.1 Why are Sales Reps Struggling for Access? 7.9.1.1 One way to Fight Against Reduced Access is to Target the System as a Whole 7.9.1.2 Multichannel Marketing to Overcome Problems of Access 7.9.2 Key Account Management (KAM) 7.9.3 Silos in Sales and Marketing 7.9.4 The Use of KOLs in Pharma Sales 7.10 Market Access 7.10.1 Emerging Stakeholders in Pharma Sales 7.10.2 The Rise of ACOs 7.10.2.1 20% of US Hospitals were Part of an ACO in 2014 7.10.3 Market Access in the EU Over the Next Ten Years 7.10.4 CSOs and Market Access Consulting 7.11 Summary: Main Trends Shaping Pharma Contract Sales 2016-2026
8. Leading Contract Sales Organisations (CSOs) 8.1 Current Industry Landscape 8.2 Quintiles 8.2.1 World Market Leader for Contract Sales and Market Access 8.2.2 New Services and Strategic Partnerships 8.2.3 Quintiles Integrated Health Services Segment Performance 2010-2015 8.2.4 Outlook for Quintiles Contract Sales to 2026 8.3 UDG Healthcare 8.3.1 Global Service Provider with Various Business Units 8.3.2 Geographic and Service Growth Through Acquisitions 8.3.3 Joint Venture with CMIC 8.3.4 UDG Healthcare Financial Performance 2010-2015 and Beyond 8.4 inVentiv Health 8.4.1 Combined CRO and CCO 8.4.2 Global Structure 8.4.3 inVentiv Health Presence in US, EU and Asia 8.4.4 Possible $500m IPO in the Near Future 8.4.5 inVentiv Health Contract Sales Outlook to 2026 8.5 Publicis Healthcare Communications Group 8.5.1 PHCG Purchases PDI Commercial Services Business 8.5.1.1 PDI Prior to Acquisition: Broad Service Portfolio, Resources which PHCG now Acquires 8.5.1.2 PDI Past Financial Performance 8.5.2 Publicis Touchpoint Solutions 8.5.2.1 New Services in Recent Years, and Tardis Medical to be Aligned with the Company 8.6 OnCall, LLC 8.6.1 Range of Services 8.6.2 Contracts with Promius Pharma 8.7 Marvecs 8.7.1 A Local Leader in Germany 8.7.2 New Services Added in Recent Years: Sales 3.0 8.8 Sofip: Contract Sales for the French Submarket 8.9 CMIC 8.9.1 CSO Business in Japan Since 2000 8.10 Leading Players in China are not Just CSOs
9. Research Interviews 9.1 Walter R. Dewees, Executive Vice-President, OnCall LLC 9.1.1 OnCall, LLC 9.1.2 Promotional Outsourcing in the US 9.1.3 Increasing Engagement via Technology-Enabled Multi-Channels 9.1.4 Growing Medical Science Liaison Function 9.1.5 Risk-Sharing Agreement 9.2 Tony Swift, Managing Director, Apodi 9.2.1 Apodi 9.2.2 Market Access Challenges in the UK 9.2.3 CSOs Can Promote Partnership Between Pharma and the NHS 9.2.4 Value Propositions Offered by CSOs 9.3 Holger C.W. Fürstenberg, Founder and Managing Director, Hilver 9.3.1 Hilver 9.3.2 Integrating CLM and Digital Strategy Remains a Challenge 9.3.3 CLM Implementation – Bridging Sales and Marketing 9.3.4 Company Culture is yet to Fully Embrace Digital Toolsets 9.3.5 Digital Tools Facilitate Unparalleled Customer Service
10. Conclusions of the Research and Analysis 10.1 The Global Pharma Contract Sales Market in 2015 10.1.1 Which Sectors Generated the Most Revenues in 2015? 10.1.2 Spending on Contract Sales is Highest in the US and EU 10.2 Outlook for the Pharma Contract Sales Market 2016-2026 10.2.1 Growth Trends for the Leading Submarkets 2016-2026 10.2.1.1 Therapeutic Sector Growth 2016-2026 10.3 Commercial Drivers for Pharma Contract Sales
List of Figures Figure 2.1 The Services Offered by CSOs that Comprise the Pharma Contract Sales Market, 2016 Figure 2.2 Outsourcing Processes in the Pharma Industry, 2016 Figure 2.3 Trends Driving the Need for New Sales Models 2016-2026 Figure 3.1 Global Pharma Contract Sales Market: Revenues ($bn), 2010-2015 Figure 3.2 Global Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 3.3 FDA New Drug Approvals, 2012-2015 Figure 3.4 Pharma Contract Sales: Market Growth Drivers, 2016-2026 Figure 3.5 Pharma Contract Sales Market: Restraints, 2016-2026 Figure 3.6 Pharma Contract Sales Market Segmented by Therapeutic Area (Line Graph): Revenue ($bn), 2015-2026 Figure 3.7 Pharma Contract Sales Market Segmented by Therapeutic Area (Area Chart): Revenue ($bn), 2015-2026 Figure 3.8 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2015 Figure 3.9 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2020 Figure 3.10 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2026 Figure 3.11 Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions), 2015 and 2030 Figure 3.12 Cardiovascular Disease Submarket Forecast: Revenue ($bn), 2015-2026 Figure 3.13 Diabetes Prevalence in Leading National Markets, 2014 Figure 3.14 Metabolic Disorders Submarket Forecast: Revenue ($bn), 2015-2026 Figure 3.15 Oncology Submarket Forecast: Revenue ($bn), 2015-2026 Figure 4.1 Pharma Contract Sales Market Segmented by Service Sectors: Revenue ($bn), 2015-2026 Figure 4.2 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2015 Figure 4.3 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2020 Figure 4.4 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2026 Figure 4.5 Contract Detailing Submarket Forecast: Revenue ($bn), 2015-2026 Figure 4.6 Contract Detailing Submarket: Drivers and Restraints, 2016-2026 Figure 4.7 Contract Non-Personal Promotion Submarket Forecast: Revenue ($bn), 2015-2026 Figure 4.8 Contract Non-Personal Promotion Submarket Drivers and Restraints, 2016-2026 Figure 4.9 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Forecast: Revenues ($bn), 2015-2026 Figure 4.10 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Market Shares (%), 2015 Figure 4.11 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Market Shares (%), 2026 Figure 4.12 Contract Teledetailing Submarket Forecast: Revenues ($bn), 2015-2026 Figure 4.13 Contract Teledetailing Submarket: Drivers and Restraints, 2016-2026 Figure 4.14 Contract eDetailing Submarket Forecast: Revenues ($bn), 2016-2026 Figure 4.15 Contract eDetailing Submarket Drivers and Restraints, 2016-2026 Figure 4.16 Medical Education Services Submarket Forecast: Revenues ($bn), 2015-2026 Figure 4.17 Medical Education Services Submarket: Drivers and Restraints, 2016-2026 Figure 4.18 Sample Management Services Submarket Forecast: Revenues ($bn), 2015-2026 Figure 4.19 Sample Management Services Submarket Drivers and Restraints, 2016-2026 Figure 5.1 Leading Regional Pharma Contract Sales Markets: Forecast Revenue ($bn), 2015-2026 Figure 5.2 Regional Composition of the Global Pharma Contract Sales Market: Market Shares (%), 2015 Figure 5.3 Regional Composition of the Global Pharma Contract Sales Market: Market Shares (%), 2020 Figure 5.4 Regional Composition of the Global Pharma Contract Sales: Market Shares (%), 2026 Figure 5.5 US Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 5.6 EU5 Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 5.7 Composition of the EU5 Pharma Contract Sales Market, 2015 Figure 5.8 Composition of the EU5 Pharma Contract Sales Market, 2026 Figure 5.9 UK Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 5.10 German Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 5.11 French Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 5.12 Italian Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 5.13 Spanish Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 5.14 Japanese Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 6.1 BRIC Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 6.2 BRIC Pharma Contract Sales Market Composition: Revenue (%), 2015 Figure 6.3 Chinese Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 6.4 Indian Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 6.5 Brazilian Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 6.6 Russian Pharma Contract Sales Market Forecast: Revenue ($bn), 2015-2026 Figure 7.1 Orphan Drug Pipeline by Disease Area, 2013 Figure 8.1 Quintiles Integrated Health Services Segment: Revenues ($bn), 2010-2015 Figure 8.2 UDG Healthcare: Ashfield Commercial and Medical Services Segment: Revenues ($bn), 2010-2015 Figure 8.3 PDI: Commercial Services Revenues ($bn), 2010-2014 Figure 10.1 Pharma Outsourcing: Market Shares (%) by Sector, 2015 Figure 10.2 Pharma Contract Sales Market: Revenues ($bn) by Sector, 2015, 2020, 2026 Figure 10.3 Pharma Contract Sales Market: Revenues ($bn), by Therapeutic Area, 2015, 2020, 2026
AbbVie Actavis Actelion Pharmaceuticals Addison Whitney Adheris Health Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) Akrikhin Alexion Allergan Amgen Apple Aquilant Specialist Healthcare Services Arbor Pharms Ireland Arena Pharmaceuticals Ashfield Commercial and Medical Services Association of the British Pharmaceutical Industry (ABPI) AstraZeneca Bain Capital Bayer Healthcare Biogaran Boehringer Ingelheim Bristol-Myers Squibb Cegedim Celesio Centers of Medicare and Medicaid Services (CMS) Chinese Ministry of Health CMIC Daiichi Sankyo Dayarn Pharma Dendreon Depomed DottNet.it Drug Safety Alliance (DSA) Eisai Eli Lilly Encore Health Resources Endo Pharmaceuticals European Commission (EC) European Federation of Pharmaceutical Industries and Associations (EFPIA) European Promotional Product Association (EPPA) Expansis Galliard German FSA Gesamtverband der Werbeartikel Wirtschaft e.V. (GWW) Go! Healthcare Marketing Google Gralise Group DCA GSK Haymarket Media Hospira In2Focus Innovex Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWiG) International Federation of Pharmaceutical Manufacturers & Associations Interpace BioPharma inVentiv Health Invida J. Knipper and Company Janssen Biotech Japan Pharmaceutical Manufacturers Association (JPMA) Kadrige Kare Pharma International Knowledge Point360 L’Agenzia Italiana del Farmaco (AIFA) Liberty Lane Partners Lupin Marvecs Medical Communications Group (MCG) Medical Council of India (MCI) MediMedia Health Menarini Asia-Pacific Merck & Co. Merqurio Pharma Merrimack Microsoft Millennium Pharmaceuticals Ministère des Affaires Sociales et de la Santé National Health Service (NHS) National Institute for Health and Care Excellence (NICE) Navicor Neurocrine Biosciences NovaMed Novartis Novella Clinical Novo Nordisk OnCall, LLC Oracle Organization of Pharmaceutical Producers of India (OPPI) Otsuka PALIO PDI Pfizer Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmagistics Pharmexx Polpharma Promius Pharma Publicis Healthcare Communications Group Publicis Touchpoint Qforma Quantia Quintiles Ramco Import Export Roche Salesforce.com Sanofi Schering-Plough Sermo Sharp Packaging Services Sinclair IS Pharma Smithkline Beecham Sofip StayinFront Symplmed Pharmaceuticals Synopia Rx Taiho Oncology Takeda Tardis Medical Temasek Holdings Tesaro Teva Pharmaceutical Industries The Dartmouth Institute for Health Policy and Clinical Practice The Medicines Company Thomas H. Lee Partners Transgenomic Transparency Committee (France) UDG Healthcare UK Department of Health United Drug Supply Chain Services United Therapeutics Univadis US Center for Disease Prevention and Control (CDC) US Congressional Budget Office (CBO) US Supreme Court Veeva Systems Vivus WHO ZS Associates Zuellig Pharma
Download sample pages
Complete the form below to download your free sample pages for Pharma Contract Sales Market 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Pharma Contract Sales Market 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Cancer Diagnostics Market Report 2021-2031
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.
Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
Visiongain Publishes Cell-Based Assays Market Report to 2030
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
